TICKERNERD
Menu
YDESYDESHealthcare · Biotechnology

YDES Stock Forecast: YD Bio Ltd. Price Predictions for 2026-2027

Last close, 3 Aug 2026
$2.30
+5.99% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 1 Aug 2026 — in the upper half.

Market cap
$153.7M
Ticker Nerd rank
50 / 100
Median analyst target
—
Analysts covering
—
Total return, dividends reinvested
1W
+0.4%
1M
+21.1%
YTD
−81.1%
From high
−90.0%
From low
+21.1%
$2
$23
Range since 28 Aug 2025, adjusted closes · the dot is the last close
Ticker Nerd rank

YDES stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores YD Bio Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
50 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
94
Issuance
90
Size
71
Growth
65
Volatility
46
Value
42
Revisions
25
Momentum
25
Quality
23

Accruals (94): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (23): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

The rank is the raw material. Whether the rules would actually own YD Bio Ltd. — and when they’d sell — is the membership.

Wall Street

YDES stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on YDES, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 28 Aug 2025Adjusted close, US dollars
$0$5$10$15$20$25Oct 25Jan 26Apr 26Jul 26YDES

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

YDES analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

YD Bio Ltd. (YDES) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
301.2×

Cheaper than 2% of US stocks

Price / book
0.5×

Cheaper than 85% of US stocks

EV / EBITDA
−0.0×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
95.6%

Higher than 93% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−444.6%

Higher than 8% of US stocks

Net margin
−276.6%

Higher than 1% of US stocks

Returns & dividend
Return on equity
−42.7%

Higher than 23% of US stocks

Return on assets
−25.4%

Higher than 16% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

YDES vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
YDESYD Bio Ltd.$153.7M
50
OKUROnKure Therapeutics, Inc.$154.3M
50
ABOSAcumen Pharmaceuticals, Inc.$155.3M
54
CDXSCodexis, Inc.$150.6M
55
KRROKorro Bio, Inc.$149.6M
38
NKTXNkarta, Inc.$149.0M
57
CNTNCanton Strategic Holdings, Inc.$148.8M
14
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. YDES appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest YDES news & analysis

YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada

GlobeNewsWire · 28 July 2026positive

YD Bio launched a six-month pilot collaboration with Numia Health to evaluate bringing its blood-based OkaiDx cancer tests to patients in British Columbia, Canada through a cross-border clinical workflow involving mobile blood collection and testing at a US laboratory.

Why it matters — The pilot represents a step toward expanding YD Bio's molecular diagnostics into the Canadian market and testing the scalability of its cross-border testing model.

FAQ

Frequently asked questions about YDES stock

How does Ticker Nerd's model rank YDES?

As at 1 Aug 2026, YD Bio Ltd. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (94 of 100).

What is the YDES stock forecast for 2030?

No analyst covering YD Bio Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for YDES are extrapolating price history, which says nothing about the business.

What does YD Bio Ltd. do?

YD Bio Ltd is a biotechnology company specializing in the advancement of DNA methylation-based cancer detection technologies, as well as innovative therapies in regenerative medicine and ophthalmology. Its primary function is to develop and commercialize diagnostic tools and treatments that leverage proprietary and exclusively licensed technologies, aiming to address critical unmet needs in healthcare.

What is the latest news on YDES?

The most recent item we track (GlobeNewsWire, 28 July 2026): "YD Bio Launches Cross-Border Cancer Testing Pilot with Numia Health to Evaluate Expanded Access to Molecular Diagnostics in Canada". YD Bio launched a six-month pilot collaboration with Numia Health to evaluate bringing its blood-based OkaiDx cancer tests to patients in British Columbia, Canada through a cross-border clinical workflow involving mobile blood collection and testing at a US laboratory.

Company

About YD Bio Ltd.

YD Bio Ltd is a biotechnology company specializing in the advancement of DNA methylation-based cancer detection technologies, as well as innovative therapies in regenerative medicine and ophthalmology. Its primary function is to develop and commercialize diagnostic tools and treatments that leverage proprietary and exclusively licensed technologies, aiming to address critical unmet needs in healthcare. Notably, YD Bio Ltd collaborates with biopharmaceutical partners to transform cutting-edge discoveries into clinically viable cancer diagnostics, such as blood-based early detection tests for pancreatic and breast cancer, currently accessible through laboratory-developed test platforms. In addition to its oncology portfolio, the company, in partnership with 3D Global Biotech, is advancing stem cell and exosome-based therapies for ocular diseases, including dry eye syndrome and corneal injuries, and plans to launch exosome-based treatments in clinical trials by 2027. YD Bio Ltd also supports global pharmaceutical research through the supply of investigational drugs and ancillary materials for clinical trials. Founded in 2013 and led by an experienced biomedical management team, YD Bio Ltd plays a strategic role in driving innovation and expanding access to advanced healthcare solutions within the biotech sector.

CEO Dr. Ethan Shen Ph.D. · Taiwan · https://www.ydesgroup.com